Fulcrum Therapeutics opened at $3.74, in line with its previous close of $3.74. In the last trading session, the stock traded between $3.68 and $3.74. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Fulcrum Therapeutics is now worth
$ 20.16
Resulting in a loss of
$ 79.84 (79.84%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.06 (-1.47%)
Day High
$3.74
Day Low
$3.68
Day Open
$3.74
Prev Close
$3.74
Volume
18,81,821
1W Return
-2.15%
1M Return
-1.86%
3M Return
0.00%
6M Return
-47.36%
1Y Return
-54.79%
Market Cap ($ Mn)
281
PE Ratio
-
PB Ratio
0.95
PEG Ratio
-
ROE
-30.36%
ROCE
-29.70%
EPS (TTM)
$-0.34
1 Week
-2.15%
1 Month
-1.86%
3 Months
0.00%
6 Months
-47.36%
9 Months
-66.10%
Kaplan Fox probes Fulcrum Therapeutics over drug halt losses
Kaplan Fox investigates Fulcrum Therapeutics for securities violations. Stock fell 51.09% after pociredir program discontinuation. FDA cited malignancy risks linked to PRC2 inhibitors as reason for halt.
1mo agoHalper Sadeh probes Fulcrum Therapeutics merger for shareholder value
Halper Sadeh LLC investigates the Fulcrum Therapeutics-Slate Medicines merger. Concerns raised over insider benefits and limited competing offers. Fulcrum shareholders to own 5.0% of the combined entity post-deal. Firm alleges potential breaches of fiduciary duties by the board.
2mo agoThird law firm probes Fulcrum-Slate merger over shareholder dilution
Three law firms, including Kahn Swick & Foti, LLC, are investigating the Fulcrum Therapeutics-Slate Medicines merger. The probes focus on potential breaches of fiduciary duty, citing the 5.0% post-merger ownership for Fulcrum shareholders and a $270 million pre-closing dividend. The combined entity will raise $245 million in private placement to fund migraine drug development.
2mo agoKaplan Fox probes Fulcrum Therapeutics after 51% stock plunge
Fulcrum Therapeutics faces a securities probe by Kaplan Fox after its stock fell 51.09% when the FDA blocked its sickle cell drug pociredir due to systemic malignancy risks linked to PRC2 inhibitors.
3mo agoFulcrum Therapeutics stock falls 51% after FDA halts program
Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. for potential securities violations after the company halted its pociredir program due to FDA safety concerns. The FDA determined that targeting the PRC2 complex carries a high risk of malignancy, leading to a 51.09% drop in Fulcrum's stock price on June 2, 2026. The law firm is seeking information from investors who may have suffered losses.
3mo agoFulcrum launches AI-native field operations management platform
Fulcrum launched its Field Operations Management (FOM) platform to consolidate utility field workflows using an AI-native approach. The platform integrates with GIS, EAM, and CRM systems, enabling utilities and contractors to manage asset management, vegetation management, and emergency response. It features embedded safety protocols and allows teams to extend capabilities with AI while maintaining security and data structures.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Fulcrum Therapeutics is now worth
$ 20.16
Resulting in a loss of
$ 79.84 (79.84%)
Note: Past profits do not guarantee future returns.
